dr. gutierrez on the safety profile of pembrolizumab-based combos in nsclc
Published 4 years ago • 69 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
0:59
dr. kerrigan on design and findings of the profile 1001 trial in ros1-mutated nsclc
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
1:13
dr. felip on immunotherapy alone or in combination in lung cancer
-
0:53
dr. perez-soler on impact of osimertinib on field of nsclc
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
1:20
resistance to immune checkpoint blockade in patients with cscc
-
4:51
lung cancer trial for patients with prior response to immunotherapy
-
4:52
targeting the immune system in non-small cell lung cancer
-
1:18
lung cancer: the impact of immunotherapy
-
3:39
what is durvalumab’s future as a treatment option in lung cancer?
-
7:20
new phase 3 data on pd-l1 vs. chemotherapy for first-line nsclc
-
1:02
teaching the immune system to attack lung cancer tumors
-
5:09
immunotherapy for lung cancer: general concepts
-
5:58
common mutations in lung cancer
-
11:09
what is the biologic rationale for checkpoint inhibitor-based combinations?
-
4:09
immunotherapy combinations: is this the future for treating lung cancer?
-
5:33
when should i combine checkpoint inhibitors & chemotherapy in frontline treatment of advanced nsclc?
-
4:13
predicting outcomes of advanced non-small cell lung cancer patients treated with pd-1/pdl
-
1:07
checkpoint inhibitors for lung cancer: combating resistance